Wang Suyu, Li Jiajun, Yan Zhipeng, Jiang Qin, Li Keran
Department of Ophthalmology, The Affiliated Eye Hospital of Nanjing Medical University, Nanjing, China.
Front Med (Lausanne). 2025 Mar 25;12:1550543. doi: 10.3389/fmed.2025.1550543. eCollection 2025.
PURPOSE: This study aimed to evaluate the therapeutic efficacy and safety of intravitreal conbercept in patients with chronic central serous chorioretinopathy (cCSC) complicated by occult choroidal neovascularization (CNV), and to explore its potential in improving visual function and various ophthalmic parameters. METHODS: This retrospective, longitudinal, comparative study included 50 patients diagnosed with cCSC and occult CNV. Patients underwent intravitreal conbercept injections and were monitored over a six-month period. Comprehensive ophthalmic evaluation included best-corrected visual acuity (BCVA), central macular thickness (CMT), subretinal fluid (SRF) status, subfoveal choroidal thickness (SFCT), and optical coherence tomography angiography (OCTA). OCTA parameters such as foveal avascular zone (FAZ) area and CNV lesion characteristics were analyzed pre- and post-treatment. Patients were categorized based on changes in CNV lesion size to identify prognostic factors influencing treatment response. RESULTS: Significant improvements were observed in mean BCVA from baseline (0.78 ± 0.50 vs. 0.32 ± 0.31, < 0.01) in all 50 eyes of the patients, except for one eye. Additionally, there were significant improvements in CMT, SRF status, SFCT, FAZ area, and CNV lesion size post-treatment ( < 0.05). Pearson correlation analysis indicated a positive correlation between baseline BCVA and CMT ( = 0.3615, = 0.0116). Changes in BCVA post-treatment correlated with alterations in CMT, SRF diameter, and CNV lesion size. Patients with a favorable treatment response had significantly lower baseline CMT (312.17 ± 57.39 vs. 428.86 ± 114.54, < 0.05) and CNV vessel diameter (17.46 ± 2.72 vs. 24.84 ± 4.02, < 0.01) compared to those with unfavorable responses. CONCLUSION: Intravitreal conbercept injection was found to be safe and effective in improving BCVA and various ophthalmic parameters in patients with cCSC complicated by occult CNV, with no significant adverse effects observed during the study period. Baseline CMT, SRF diameter, CNV lesion size, and mean CNV vessel diameter were identified as valuable indicators for assessing treatment response and prognosis. These findings provide important insights for the clinical management and prognostic evaluation of cCSC patients with occult CNV, highlighting the utility of multimodal imaging in assessing treatment outcomes.
目的:本研究旨在评估玻璃体内注射康柏西普治疗慢性中心性浆液性脉络膜视网膜病变(cCSC)合并隐匿性脉络膜新生血管(CNV)患者的疗效和安全性,并探讨其在改善视功能和各项眼科参数方面的潜力。 方法:本回顾性、纵向、对照研究纳入了50例诊断为cCSC合并隐匿性CNV的患者。患者接受玻璃体内康柏西普注射,并在6个月内进行监测。综合眼科评估包括最佳矫正视力(BCVA)、中心黄斑厚度(CMT)、视网膜下液(SRF)状态、黄斑中心凹下脉络膜厚度(SFCT)以及光学相干断层扫描血管造影(OCTA)。分析治疗前后OCTA参数,如黄斑无血管区(FAZ)面积和CNV病变特征。根据CNV病变大小的变化对患者进行分类,以确定影响治疗反应的预后因素。 结果:除1只眼外,所有50只患眼中患者的平均BCVA较基线均有显著改善(0.78±0.50 vs. 0.32±0.31,P<0.01)。此外,治疗后CMT、SRF状态、SFCT、FAZ面积和CNV病变大小均有显著改善(P<0.05)。Pearson相关分析表明,基线BCVA与CMT呈正相关(r=0.3615,P=0.0116)。治疗后BCVA的变化与CMT、SRF直径和CNV病变大小的改变相关。治疗反应良好的患者与反应不佳的患者相比,基线CMT显著更低(312.17±57.39 vs. 428.86±114.54,P<0.05),CNV血管直径也显著更低(17.46±2.72 vs. 24.84±4.02,P<0.01)。 结论:玻璃体内注射康柏西普被发现对于改善cCSC合并隐匿性CNV患者的BCVA和各项眼科参数是安全有效的,在研究期间未观察到显著不良反应。基线CMT、SRF直径、CNV病变大小和平均CNV血管直径被确定为评估治疗反应和预后的有价值指标。这些发现为cCSC合并隐匿性CNV患者的临床管理和预后评估提供了重要见解,突出了多模态成像在评估治疗结果方面的实用性。
J Ophthalmol. 2019-5-7
Annu Rev Vis Sci. 2024-9
Prog Retin Eye Res. 2024-7
Graefes Arch Clin Exp Ophthalmol. 2024-5
Eye Vis (Lond). 2023-7-11
Life (Basel). 2023-6-17